Childhood ALL And Risk Of Delayed Neurodevelopment
A new study provides novel insights into the cognitive effects of childhood acute lymphoblastic leukemia (ALL) and of chemotherapeutic treatment in long-term survivors of ALL.
A new study provides novel insights into the cognitive effects of childhood acute lymphoblastic leukemia (ALL) and of chemotherapeutic treatment in long-term survivors of ALL.
Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now.
Scientists may be on the road to solving the mystery of a group of mostly incurable blood diseases called myelodysplastic syndromes (MDS), which cause people to have immature, malfunctioning bone marrow cells could lead to leukemia.
People with blood cancer are less likely to understand their diagnosis than those with any other type of cancer, according to a new analysis by Bloodwise
Childhood leukemia is a diagnosis that no family ever wants to endure. While the treatment of most types of leukemia has improved steadily over the years, a few specific types remain very difficult to treat. One of these is called "mixed-lineage leukemia," and the survival rate for children affected by this cancer is only around 50%
Lymphatic vessels actively contribute to the spread of cancer metastases from various organs. This unexpected realization is the result of a joint study by researchers from ETH Zurich and the University Hospital Zurich as part of the research initiative Skintegrity
The human stress hormone cortisol has been identified by scientists at the University of Kent as a key factor when the immune system fails to prevent leukemia taking hold
Previous research has revealed that patients with acute myeloid leukemia who also have a particular mutation in a gene called NPM1 have a higher rate of remission with chemotherapy.
Childhood leukemia is a diagnosis that no family ever wants to endure. While the treatment of most types of leukemia has improved steadily over the years, a few specific types remain very difficult to treat.
Previous research has revealed that patients with acute myeloid leukemia who also have a particular mutation in a gene called NPM1 have a higher rate of remission with chemotherapy.
Multiple-myeloma has been a rare disease that had been diagnosed in more than 30,000 people each year in the United States. Only half of the patients with multiple myeloma are expected to survive five years after their diagnosis.
Chimeric antigen receptor T-cell therapy has produced some dramatic responses in pediatric acute lymphoblastic leukemia, but the responses have been less spectacular in other hematologic malignancies, and they have been disappointing in solid tumors.